AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca said its experimental, long-acting antibody-based Covid-19 combination treatment aims to protect those who aren't able to be vaccinated.

AstraZeneca to Supply Extra 500,000 Doses of Covid-19 Treatment to U.S.

Most medicine regulators have advised against the temporary ban, which will delay already-slow vaccination campaigns on the continent.

Europe's shelving of AstraZeneca shot delays further its troubled vaccination campaigns

The World Health Organization said that global distribution of the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine remains unruffled, though much of Europe has stopped using the shot after reports of blood clots in some people shortly after immunization, reports Washington Post. The EMA has not recommended that authorities suspend the use and WHO also came out to advise against halting vaccinations.

Suspensions In Europe Will Not Disturb AstraZeneca Vaccine's Global Roll Out: Report

Decisions by at least 16 countries to suspend use of the AstraZeneca vaccine is "baffling", "reckless" and "political", experts have said. A growing list of nations has pulled the shot from use, with most of the biggest nations of Europe deciding to stop on Tuesday.

The growing list of countries suspending use of the AstraZeneca vaccine may be doing much more harm than good, experts say

AstraZeneca, international regulators, and numerous experts all say the vaccine is safe and there is no evidence it is linked to blood clots.

AstraZeneca Vaccine: Here's What To Expect As Europe's Medicines Regulator And The WHO Meet To Review Shot

Late-stage trial data of AstraZeneca's coronavirus vaccine might not look good—and that's a good opportunity to buy the Anglo-Swedish drug company, according to an analyst note released on Tuesday.

AstraZeneca Trial Data May Not Be Impressive, Setting Up A Buying Opportunity, Says Jefferies

AZD7442 is being evaluated for the prevention and treatment of COVID-19 in late-stage trials in more than 9,000 participants around the world.

AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail

As Europe faces a third wave of Covid-19, the list of countries that have banned the AstraZeneca vaccine is getting longer.

Which Countries Have Stopped Using The AstraZeneca Vaccine? [Infographic]

Experts say the decision by some European countries to suspend use of the AstraZeneca/University of Oxford Covid shot could be damaging.

'The damage is done': Europe's caution over AstraZeneca vaccine could have far-reaching consequences

AstraZeneca PLC (LON:AZN) got a boost on Tuesday as the COVID-19 vaccine developed with Oxford University will be reviewed by experts worldwide. The World Health Organization (WHO) and the European Medicines Agency (EMA) will hold separate meetings after 11 EU countries halted the rollout of the jab, alongside Thailand, Venezuela and Indonesia.

AstraZeneca gets boost as WHO, EU regulator start reviews of COVID-19 vaccine

Two additional countries opted to suspend the use of the AstraZeneca vaccine in Europe on Tuesday as regulators proceed with a new review into its side effects.

More European countries suspend AstraZeneca shot as regulators review its side effects

AstraZeneca was upgraded to buy from hold at Jefferies, and its price target lifted to 8850 pence ($61.05 per U.S.-listed share) from 8250 pence. Analysts led by Peter Welford said AstraZeneca's "impressive" revenue and profit trajectory is compelling relative to European pharma peers, and the approaching close of the Alexion acquisition will make the deal's merits more widely appreciated.

Buy AstraZeneca on possibly 'underwhelming' vaccine trial data, Jefferies says

Health experts say they are disappointed and confused by the flurry of suspensions of the coronavirus vaccine developed by Oxford-AstraZeneca.

Doctors baffled by suspension of AstraZeneca vaccine over blood clot fears

The chief executive of AstraZeneca - whose COVID-19 vaccine has been temporarily suspended in several European countries - is "on a hot seat and knows it", said French Industry Minister Agnes Pannier-Runacher.

French Industry Minister: AstraZeneca CEO is 'on a hot seat'

AstraZeneca PLC (LON:AZN) announced that it has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, billing it an extra US$205mln. The drug is a long-acting antibody (LAAB) combination for the prevention and treatment of COVID-19, currently being tested in late-stage trials in more than 9,000 participants around the world.

AstraZeneca extends US agreement for COVID-19 treatment candidate

Issues around the AstraZeneca-Oxford vaccine could hurt global trade — that's bad news for Asia, said Steve Cochrane, chief APAC economist at Moody's Analytics.

AstraZeneca vaccine halt could slow down Asia's economic recovery, says economist

Germany, Italy, and France joined the list of countries that have suspended the use of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine over reports of blood clots in some recipients, as per Reuters. What Happened: Denmark and Norway stopped giving the shot last week after reporting a couple of cases of bleeding, blood clots, and a low platelet count.

Germany, France Join List Of Countries Suspending AZN's COVID-19 Vaccine; WHO Urges Not To Halt Vaccinations

The nations said they suspended the vaccine as a cautionary step, as regulators continued to investigate reports of blood clots in a small number of people who received it.

Germany, France, Italy Join Countries In Suspending Use Of AstraZeneca Vaccine Over Blood Clot Concerns

AstraZeneca's (LON: AZN) COVID-19 vaccine that it developed in collaboration with the University of Oxford recently came under fire after reports of blood clots in some patients. On Monday, Ireland, Germany, and the Netherlands announced to have suspended the use of the vaccine on fears of such dire such effects.

Ireland, Germany, and the Netherlands suspend use of AstraZeneca's COVID-19 vaccine

France joins list of European countries suspending AstraZeneca vaccine use

AstraZeneca (AZN) announces analysis of safety data of more than 17 million people vaccinated with its vaccine, demonstrating no increased risk of blood clot.

AstraZeneca (AZN) Defends COVID-19 Vaccine Safety With Data

AstraZeneca has said there is no increased risk of blood clots from its Covid-19 vaccine, as the Netherlands and Ireland joined a fast-growing list of European countries suspending inoculations.

AstraZeneca Defends Vaccine After More Countries Suspend Its Use

AstraZeneca insisted Sunday that its COVID-19 vaccine is safe in its firmest rebuttal yet to concerns over its safety that have led to seven countries suspending its use. Some national health authorities — mainly in Europe — have stopped using the shot while they investigate whether it could be linked to instances of blood clots in people who took it.

AstraZeneca insists its COVID-19 vaccine is safe and there is no link to blood clots, as 7 countries suspend its use

AstraZeneca has found no evidence that its COVID-19 vaccine increases the risk of blood clots like those that led several countries to halt their rollout of the shot. The British drugmaker tried to quell safety concerns after blood clots emerged in some people who had been vaccinated, prompting about a dozen nations to stop using.

AstraZeneca finds no evidence COVID vaccine raises blood clot risk

The UK government is scrambling to pour cold water on fears that AstraZeneca's COVID-19 vaccine causes blood clots. The vaccine was developed by Oxford University, and authorized in the UK last December. Prime Minister Boris Johnson, Health Minister Matt Hancock hailed it at the time as a feat of British resolve and skill.

News for AstraZeneca Stock (AZN)